Table 1. Patient characterisics.
| # | Age/Gender | Primary EGFR-TKIs | Sensitive mutation | T790M status before Afa+Bev/Site/Method | Response/PFS (mo) | T790M status after Afa+Bev/Site/Method | Duration/Chemotherapy between PD and rebiopsy |
|---|---|---|---|---|---|---|---|
| 01 | 79/F | G, E | L861Q | T790M (−)/Lung/Clamp | PR/13.1 | / | / |
| 02 | 56/F | G, E | L858R | T790M (−)/Cardiac effusion/Clamp | SD/5.1 | T790M (−)/Cardiac effusion/Clamp | 0 mo/None |
| 03 | 55/F | E | Del-19 | T790M (−)/Lung/Clamp | PD/1.4 | T790M (+)/Pleural effusion/Clamp | 0 mo/None |
| 04 | 62/F | G, E | L858R | T790M (−)/Lung/Clamp | SD/3.4 | T790M (−)/Lung/Clamp | 0.4 mo/None |
| 05 | 63/M | G | Del-19 | T790M (−)/Lung/Clamp | PR/9.3 | T790M (+)/Lung/Clamp | 0.4 mo/None |
| 06 | 73/M | E | L858R | T790M (−)/Lung/Clamp | SD/8.7 | T790M (+)/Lung/Clamp | 8.0 mo/CBDCA+PEM |
| 07 | 59/M | G, E | Del-19 | T790M (−)/Pleural effusion/Clamp | PD/1.0 | / | / |
| 08 | 73/M | G, E | L858R | T790M (−)/Lung/Clamp | SD/2.9 | / | / |
| 09 | 82/M | G | Del-19 | T790M (+)/Lung/Clamp | SD/10.3 | / | / |
| 10 | 62/M | E | Del-19 | T790M (−)/Pleural effusion/Clamp | PR/10.1 | T790M (+)/Pleural effusion/MBP-QP | 0 mo/None |
| 11 | 79/F | G | Del-19 | T790M (+)/Pleural effusion/Clamp | SD/2.5 | T790M (+)/Pleural effusion/MBP-QP | 0 mo/None |
| 12 | 81/F | G, E | Del-19 | T790M (+)/Lung/Clamp | SD/9.1 | T790M (+)/Lung/MBP-QP | 0.4 mo/None |
| 13 | 81/F | G | Del-19 | T790M (−)/Lung/Clamp | SD/6.3 | T790M (+)/Lung/MBP-QP | 7.4 mo/GEM+Bev, nab-PTX |
| 14 | 63/F | G, Afa | Del-19 | T790M (+)/Lung/Clamp | SD/2.6 | / | / |
| 15 | 65/F | G | Del-19 | T790M (+)/Pleural effusion/Clamp | PD/1.1 | T790M (+)/Pleural effusion/Clamp | 0 mo/None |
| 16 | 55/M | G | L858R | T790M (+)/Lung/Clamp | SD/3.5 | / | / |
| 17 | 66/M | G | Del-19 | T790M (−)/Lung/Clamp | SD/1.5 | / | / |
| 18 | 74/F | G | Del-19 | T790M (+)/Lymph node/Clamp | SD/3.9 | / | / |
| 19 | 66/M | G | Del-19 | T790M (+)/Pleural effusion/Clamp | SD/7.8 | T790M (+)/Pleural effusion/Clamp | 0 mo/None |
| 20 | 80/M | E | Del-19 | T790M (+)/Pleural effusion/Clamp | PR/5.8 | / | / |
| 21 | 64/F | G | Del-19 | T790M (−)/Lung/Cobas | PR/5.1 | T790M (+)/Lung/Clamp | 3.4 mo/Afa |
| 22 | 48/F | G | Del-19 | T790M (−)/Lung/MBP-QP | SD/2.9 | T790M (−)/Lung/Cobas | 0.1 mo/None |
| 23 | 68/F | G, E, Afa | Del-19 | T790M (−)/Lung/MBP-QP | SD/5.5 | / | / |
| 24 | 80/M | E | Del-19 | T790M (−)/Lung/MBP-QP | SD/7.3 | T790M (−)/Lung/Clamp/MBP-QP | 0.3 mo/None |
| 25 | 86/F | G, E | L858R | T790M (+)/Lung/Clamp | SD/8.1 | / | / |
| 27 | 79/F | G | L858R | T790M (+)/Lung/Clamp | SD/9.3 | / | / |
| 28 | 74/F | G | L858R | T790M (−)/Lung/MBP-QP | SD/4.1 | T790M (+)/Lung/MBP-QP | 0.2 mo/None |
| 29 | 46/F | G | Del-19 | T790M (+)/Lung/MBP-QP | SD/9.5 | T790M (+)/Lung/MBP-QP | 0.4 mo/None |
| 30 | 65/F | E | L858R | T790M (−)/Lung/MBP-QP | SD/3.1+ | / | / |
| 31 | 67/M | Afa | Del-19 | T790M (+)/Pleural effusion/Clamp | PR/9.9+ | / | / |
| 32 | 51/F | G, E, Afa | Del-19 | T790M (−)/Lung/MBP-QP | SD/7.8 | T790M (+)/Lung/MBP-QP | 0.4 mo/None |
| 33 | 62/F | E, Afa | Del-19 | T790M (−)/Lung/Cobas | SD/2.8 | T790M (−)/Pleural effusion/Clamp | 3.3 mo/4 regimens# |
Abbreviations: M, male; F, female; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; G, gefitinib; E, erlotinib; Afa, afatinib; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; mo, months; CBDCA, carboplatin; PEM, pemetrexed; GEM, gemcitabine; Bev, bevacizumab; nab-PTX, nanoparticle albumin bound-paclitaxel; Clamp, peptide nucleic acid-locked nucleic acid PCR clamp method; and mutation-biased PCR quenching probe method.
Case 26 and 34 were ineligible.
#, docetaxel plus ramucirumab, nab-PTX, Gefitinib+GEM, S-1+Bev.